Literature DB >> 17090605

Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats.

Iddo Z Ben-Dov1, Orit Pappo, Miri Sklair-Levy, Hillel Galitzer, Yaron Ilan, Tally Naveh-Many, Justin Silver.   

Abstract

BACKGROUND: Lanthanum (La) carbonate is an effective phosphate-binder, used to reverse hyperphosphataemia due to chronic kidney disease. Some recent studies in rodents have cast safety uncertainties. The aims of this study were to examine the effects of La on parathyroid hormone (PTH) gene expression and hepatic toxicity.
METHODS: Uraemia was induced in rats by a 0.3% adenine-containing diet for 2 weeks. Thereafter, rats were maintained for 4 weeks on an adenine diet with 1.5 or 3% La. Normal, uraemic, and uraemic rats fed a low-phosphorus (P) diet served as controls.
RESULTS: Azotaemia developed in all adenine-fed rats. La of 3%, but not 1.5% La, decreased serum P to normal in uraemic rats. Both La 1.5 and 3% decreased urine P excretion. Plasma PTH was tripled in uraemic compared with normal rats. Both the 3.0% La and the low-P diet decreased PTH to normal. PTH mRNA content was increased 2-fold in uraemic compared with normal rats. The 3% La or the low-P diet decreased PTH mRNA levels to normal in uraemic rats. Liver enzymes were normal in all groups. Adenine-induced uraemia decreased liver weight with no additional effect of La. Liver weights corrected for body-weights were the same in all study groups, including the La group. Therefore, La had no effect upon absolute or corrected liver weight. Liver magnetic resonance imaging and microscopy did not reveal toxic changes due to La.
CONCLUSIONS: These findings confirm that in rats with adenine-induced uraemia, the P-binder La reverses the hyperphosphataemia and hyperparathyroidism. They are the first demonstration that La decreases PTH gene expression. Importantly, we found no evidence of drug-induced liver toxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090605     DOI: 10.1093/ndt/gfl623

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

1.  Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.

Authors:  Piergiorgio Bolasco
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

2.  Linear nevus sebaceous syndrome with hypophosphatemic rickets with elevated FGF-23.

Authors:  Ryo Narazaki; Kenji Ihara; Noriyuki Namba; Hiroshi Matsuzaki; Keiichi Ozono; Toshiro Hara
Journal:  Pediatr Nephrol       Date:  2011-12-29       Impact factor: 3.714

Review 3.  Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease.

Authors:  Mario Cozzolino; Maurizio Gallieni; Sabina Pasho; Giuditta Fallabrino; Paola Ciceri; Elisa Maria Volpi; Laura Olivi; Diego Brancaccio
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

4.  The parathyroid is a target organ for FGF23 in rats.

Authors:  Iddo Z Ben-Dov; Hillel Galitzer; Vardit Lavi-Moshayoff; Regina Goetz; Makoto Kuro-o; Moosa Mohammadi; Roy Sirkis; Tally Naveh-Many; Justin Silver
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

5.  A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate.

Authors:  Felix Bronner; Boris M Slepchenko; Michael Pennick; Stephen J P Damment
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 6.  Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?

Authors:  Thanh-Mai Vo; Sinee Disthabanchong
Journal:  World J Cardiol       Date:  2014-05-26

7.  Lanthanum carbonate, a phosphate binder, inhibits calcification of implanted aortic allografts in a rat model.

Authors:  Osamu Kinoshita; Haruo Yamauchi; Noboru Motomura; Minoru Ono
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-10-29

8.  Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure.

Authors:  Stephen Damment; Roger Secker; Victor Shen; Victor Lorenzo; Mariano Rodriguez
Journal:  Nephrol Dial Transplant       Date:  2010-11-22       Impact factor: 5.992

9.  The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients.

Authors:  Takashi Shigematsu; Yuri Nakashima; Masaki Ohya; Koichi Tatsuta; Daisuke Koreeda; Wataru Yoshimoto; Shintaro Yamanaka; Toshifumi Sakaguchi; Yoshiyuki Hanba; Toru Mima; Shigeo Negi
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-05-29

10.  Evaluation of cerium oxide as a phosphate binder using 5/6 nephrectomy model rat.

Authors:  Akiko Hashimoto; Jiaqi Gao; Yuki Kanome; Yukihiro Ogawa; Masaharu Nakatsu; Masahiro Kohno; Koji Fukui
Journal:  BMC Nephrol       Date:  2022-08-08       Impact factor: 2.585

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.